[Correction of the alphamimetic effects of metaraminol by nicergoline].
In this work, the authors are studying the cardio-vascular effects of nicergoline. To do so, the drug is made to compete with metaraminol whose dominant alphamimetic effects are known. This experimentation was performed in 7 patients in coma stage III or IV and whose vascular receptors were active. Those 7 patients were submitted continuous metaraminol perfusion and a steady state vasoconstriction was thus obtained. A single intravenous injection of 10 mg nicergoline resulted in vasodilation with a fall in vascular resistance and a moderate fall in mean blood pressure. Cardiac output remained unchanged. This work confirme thus the alphasympatholytic effects of nicergoline.
D001794:Blood Pressure / Q000187:drug effects*; D003128:Coma / Q000188:drug therapy*; D004347:Drug Interactions; D004873:Ergolines / Q000494:pharmacology*; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008680:Metaraminol / Q000009:adverse effects / Q000627:therapeutic use*; D009530:Nicergoline / Q000009:adverse effects / Q000494:pharmacology*; D011941:Receptors, Adrenergic / Q000187:drug effects*; D014655:Vascular Resistance / Q000187:drug effects*
D004873:Ergolines; D011941:Receptors, Adrenergic; D008680:Metaraminol; D009530:Nicergoline
Correction des effets alphamimétiques du métaraminol par la nicergoline